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Elevated calcitonin precursor levels are related to mortality in an
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Background:  Increased serum levels of procalcitonin (ProCT) and its
component peptides have been reported in humans with sepsis. Using a hamster
model of bacterial peritonitis, we investigated whether serum ProCT levels are
elevated and correlate with mortality and hypocalcemia.
Results: Incremental increases in doses of bacteria resulted in proportional
increases in 72 h mortality rates (0, 20, 70, and 100%) as well as increases in
serum total immunoreactive calcitonin (iCT) levels at 12 h (250, 380, 1960, and
4020 pg/ml, respectively, vs control levels of 21pg/ml). Gel filtration studies
revealed that ProCT was the predominant (>90%) molecular form of serum iCT
secreted. In the metabolic experiments, total iCT peaked at 12 h concurrent with
the maximal decrease in serum calcium.
Conclusions: In this animal model, hyper-procalcitoninemia was an early
systemic marker of sepsis which correlated closely with mortality and had an
inverse correlation with serum calcium levels.
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Introduction
There are approximately 400000 cases of sepsis reported
each year in the USA, leading to about 100000 deaths
annually [1–3]. Indeed, mortality from sepsis in most
series is reported to be between 25 and 40%, with Gram-
negative bacteria being the most commonly encountered
pathogens [3–5]. The severity of sepsis may distinguish
those who may benefit from therapeutic blockade of their
excessive and maladaptive immune response, from those
who may not. Consequently, a practical way to determine
the presence and severity of sepsis is essential. Although
systems of evaluation based on clinical observations and
physiologic parameters are helpful, they have been of
limited use for predicting morbidity and mortality in indi-
viduals with inflammatory conditions, especially in surgi-
cal populations [6–10]. An early indicator of tissue injury
should improve the predictive capability of these systems.
Although several cytokines have been proposed as
markers of disease severity, they are often transiently ele-
vated, or detected only in local pools [7]. In this regard,
recent studies in humans have revealed that the prohor-
mone of calcitonin (CT), procalcitonin (ProCT), as well as
its component peptides offer promise of being early and
useful predictive markers of systemic inflammation
[11–13].
CT is a neuroendocrine (NE) peptide that was once
thought to be exclusively a hormone of thyroid origin. Its
principal function appears to be the conservation of body
calcium stores in certain physiologic states such as growth,
pregnancy and lactation, and the maintenance of bone
mineral in emergency situations by means of attenuation
of the activity of osteoclasts [14]. Further study has
revealed that CT is produced extrathyroidally by NE cells
throughout the body, and may have multiple functions
[15,16]. CT is initially biosynthesized as a larger ProCT polypep-
tide which is subsequently cleaved enzymatically into its
components, including the mature, active hormone
(Fig1). Interestingly, in humans with severe systemic
inflammation, very high serum levels of ProCT and its
component peptides are accompanied by normal or only
slightly increased levels of mature CT [17]. In order to
investigate whether serum ProCT levels might correlate
with the severity of illness in sepsis, and thus might
provide a convenient marker, we employed a rodent
model of quantifiable Escherichia coli peritonitis, modified
for use in the hamster [18]. This model was then utilized
to determine the metabolic perturbations associated with
the procalcitonin peptide levels observed with sepsis.
Materials and methods
Animals
Male Golden-Syrian hamsters weighing 80–140g (Harlan
Animals, Indianapolis, Indiana, USA) were housed in a
controlled environment and were exposed to 12h light-
–dark cycles. The animals had unrestricted access to water
and standard rodent chow throughout the experiments.
This study was approved by the Institutional Animal Care
and Use Committee at the Veterans Affairs Medical
Center, Washington, DC.
Bacteria
Escherichia coli (O18:K1:H7) were obtained from Dr Alan S
Cross, Division of Communicable Diseases and Immunol-
ogy, Walter Reed Army Institute of Research, Washing-
ton, DC, USA. The bacteria were grown in 100 ml of LB
Broth (Fisher Scientific, Pittsburgh, Pennsylvania, USA)
at 37°C in a shaker water bath to log phase and stored in
250ml aliquots at –70°C until use.
On the day of an experiment, a 250ml aliquot of bacteria
was thawed and grown in 100ml LB broth at 37°C in a
shaker water bath to log phase. The optical density of the
specimen was measured at 600nm on a Stasar III spec-
trophotometer (Gilford Instruments, Oberlin, Ohio, USA)
and quantified by interpolation on a previously con-
structed curve of optical density plotted against colony
forming units (cfu). Additional specimens were taken from
the stock solution, and diluted and plated to confirm the
counts estimated by spectrophotometry.
Intra-abdominal pellets
Bacterial suspensions of 2.0´108, 1.0´109, 2.0´109, or
4.0´109cfu/ml E coli were pipetted in 0.5ml aliquots into
8mm plastic embedding molds (Shandon-Upshaw, War-
rington, Pennsylvania, USA). Each pellet for implantation
was made by adding 0.5ml sterile molten agar at 50°C to
the bacterial suspension, after which the mixture was
allowed to solidify at room temperature. The final number
of viable colony forming units of bacteria in each pellet
was 1.0´108, 5.0´108, 1.0´109, or 2.0´109cfu/pellet.
Experimental protocol
Mortality studies
Individual hamsters were assigned to four groups
(n=16/group) to receive progressively increasing inocula
of bacteria. After adequate anesthesia with 50mg/kg pen-
tobarbital via intraperitoneal injection, the abdomen of
each animal was prepared with 70% alcohol and incised in
the midline. Bacterial sepsis was induced by implanting
one pellet in the right lower quadrant of the peritoneal
cavity of each animal. The abdominal incisions were then
closed with non-absorbable suture. Animals were caged
individually, given unrestricted access to water and rodent
chow and monitored for mortality over a 72h period.
Total iCT studies
After intraperitoneal implantation of agar pellets with pro-
gressively increasing doses of E coli, separate groups
(n=10/group) were killed for serum total immunoreactive
(i)CT determinations. Since mortality was evident but not
prohibitively high at 12h, we chose this timepoint to
determine serum total iCT levels. Therefore, 12h after
animals were challenged with E coli, they were anes-
thetized with intraperitoneal pentobarbital (50mg/kg) and
exsanguinated by open cardiac puncture. The blood was
collected in individual tubes and centrifuged at 3000rpm
for 15min. The serum specimens were transferred to indi-
vidual glass tubes, sealed with parafilm and stored at
–70°C until radioimmunoassay.
Serum was also obtained from a patient with documented
Gram-negative sepsis and was stored at –70°C to be
assayed with the hamster serum samples following G-75
Sephadex gel filtration for the purpose of comparison of
molecular forms as described below.
Metabolic studies
Male hamsters (n=16/group) underwent intraperitoneal
implantation of agar pellets impregnated with 2´109cfu
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Figure 1
The procalcitonin (ProCT) molecule and its components. AminoproCT
= amino terminus of procalcitonin; immature CT = the 33 amino acid,
non-amidated CT; CCP-I = calcitonin carboxyterminus peptide-I. In
normal people, in addition to the free, active, mature CT, small amounts
of ProCT, aminoproCT, CCP-I, the conjoined CT:CCP-I peptide, and
the immature CT circulate [18]. The amino acid sequence of the rat
mature CT is very similar to that of humans, and the sequence of
hamster CT, although not yet known, reveals, by immunoassay studies,
a marked homology with the rat.
proCT
AminoproCT Immature CT CCP-IE coli (O18: K1: H7), according to the above implantation
protocol. This high dose was chosen for its ability to
induce a significant increase of ProCT at 12h in the pro-
ceeding experiments. Animals were killed in the previ-
ously described fashion at 3, 6, 12 or 24h after septic
challenge. Their sera were analyzed for serum total iCT
per the radioimmunoassay described below, as well as for
total serum total calcium and serum albumin using a stan-
dard serum multichannel analyzer.
Radioimmunoassay
The samples were allowed to warm to room temperature
and were pipetted into labeled glass test tubes in 1.0ml
aliquots, to which 100ml dextran blue (B-2000,
2000000 Da; Sigma Chemical Co, St Louis, Missouri,
USA) was added. Five milliliter glass columns were rinsed
with 1M ammonium hydroxide:acetonitrile (1:1) and
deionized water, after which fine-grade polyacrylamide gel
columns (5ml) were prepared (BioGel P-2; 100–200 mesh;
Bio-Rad Laboratories, St Louis, Missouri, USA) using a
glass bead to support the gel. The samples were applied to
the columns and eluted with 0.1M ammonium bicarbonate
containing 0.1% Triton X-100 (Pierce, Rockford, Illinois,
USA). The specimens containing dextran blue were then
recovered in their original test tubes, to which ethyl alcohol
was added in a 2:1 volume ratio. These mixtures were then
centrifuged at 3000rpm for 30min, after which the super-
natant for each was decanted into new tubes and the pellet
discarded. The solvent was removed using a Savant Speed-
Vac Plus (SC110A) over 2–4h. The residue for each sample
was then reconstituted to the original specimen volume
using gelatin buffer (0.2% gelatin in borate buffer with
0.01% merthiolate and 0.1% Triton X-100). Using these
techniques, peptide recovery is approximately 80%.
The radioimmunoassay design was similar to that previ-
ously reported [19]. Initially, hamster serum total iCT from
gel filtration studies was determined by using an antiserum
to the carboxyl-terminal portion of mature human CT, Ab-
4. This antiserum reacts with the CT molecule, whether it
is in the free, amidated, 32-amino acid mature form, or
within its precursor propeptides [ie procalcitonin, the con-
joined calcitonin:calcitonin carboxypeptide-I (CT:CCP-1),
or the free immature, unamidated CT]. Subsequent studies
were performed with a new antibody, R1B4, which has ten
times the crossreactivity of Ab-4 with the prohormone. The
buffer was 0.2% gelatin (0.13M H3BO3 containing 9g NaCl,
2g gelatin, 1ml Triton-X 100 and 0.1g merthiolate/l at
pH=7.5). The antiserum was preincubated with standards
or unknowns (20–100ml) in 0.2ml at 4°C for 4 days. After
addition of 50ml 125I-hCT, and 200ml gelatin buffer, incu-
bation was continued for 2days. After adding 50ml goat anti-
rabbit IgG bound to iron particles, incubation was
continued in 0.5ml for 1 day. Bound and free hormone were
separated with magnetic tube racks. Maximum bound
= 37%; sensitivity = 1 g; 50% B/Bo = 50pg. 
Gel filtration
Similarly to work previously reported [20], constituted
extracts, in 1–10ml 0.2% gelatin or 0.2% HSA, were
applied to calibrated 2.5´100 cm columns containing G-
75 superfine Sephadex (Pharmacia Biotech, Piscataway,
New Jersey, USA) suspended in 0.1% human serum
albumin (1g HSA, 0.1mol NH4HCO3 and 0.1g merthio-
late/l at pH=7.5) at 4°C. One hundred fractions (120 drops
or 5.5ml/tube) were collected during 48h in 16´100mm
borosilicate glass culture tubes. The void volume (VV) was
based on the peak elution volume (EV) of blue dextran,
and the salt volume (SV) was based on the peak EV of
Na125I. The Kav for individual components was deter-
mined according to the formula: Kav = (EV–VV)/(SV–VV).
Results
Mortality
The mortality rates at 72h for animals receiving progres-
sively increasing doses of bacteria (n=16/group) were 0,
20, 70, and 100%, respectively. Differences in mortality
between all groups, including control animals (n=17),
were significant by Chi-square (P=0.001). Furthermore,
these values represent a direct relationship between the
size of the inoculum of E coli and mortality (Fig 2).
Serum total iCT levels
Hamsters which were subjected to these graded doses of
sepsis (n=10/group) had serum total iCT levels at 12h
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Figure 2
Relationship between inoculum of Escherichia coli and mortality. Low
dose = 1.0´108cfu/pellet, medium dose = 5.0´108cfu/pellet, high
dose = 1.0´109cfu/pellet, and highest dose = 2.0´109cfu/pellet.
Mortality for low dose was 0%. *Significantly different from other
groups per Chi-square analysis, P<0.001.
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20 *(mean±SEM) of 250±90, 380±60, 1960±490, and
4020±510pg/ml, respectively. Control animals (n=17) had
serum total iCT levels of 21±2pg/ml. All groups were sta-
tistically distinct, except between 0 and 20% mortality
(P=0.001, Kruskal-Wallis one-way ANOVA; Fig 3).
Molecular species of the total serum iCT
The molecular species of the total serum iCT in the
serum was determined by radioimmunoassay of fractions
obtained from Sephadex gel filtration of pooled hamster
sera as described above. The molecular mass of the pre-
dominant species of iCT measured (ie >90%) was approxi-
mately 14000 Da. From previous data [31], it is known
that this fraction corresponds to ProCT, which in humans
is 12795 Da. As shown in Fig 4, this molecular fraction in
the hamster co-elutes with the ProCT fraction in the
serum of a septic patient [17].
Metabolic studies
Serum total iCT levels among groups exposed to a high
dose of E coli (n=13–15) and killed at 3, 6, 12 and 24h
increased from a baseline of 21±2pg/ml (mean±SEM) to
78±3, 542±100, 3570±920, and 4240±1080pg/ml, respec-
tively. The changes in serum total iCT at all time points,
except between 12 and 24h, were statistically significant
(one-way ANOVA, P=0.001). 
Total serum calcium levels at these timepoints were
11.6±0.1, 12.1±0.2, 9.4±0.2, and 10.6±0.4 mg/dl. The
decrease at 12h was statistically significant per Mann-
Whitney rank sum test (P<0.05). Simple linear regression
reveals an inverse correlation between total calcium levels
and total iCT (r=–0.81). Serum albumin levels varied
minimally at 3, 6, 12 and 24h from a baseline of
3.3±0.1g/dl, and therefore did not account for the
decrease in measured calcium.
Discussion
The characteristics of the inflammatory response in sepsis
suggest that successful treatment requires a clinically
useful marker which can indicate the severity of illness
and which is expressed early enough in the sepsis cascade
to allow therapeutic interventions to be initiated in a
timely manner [4]. Additionally, insights into the biosyn-
thesis, regulation, and physiologic activity of such a
marker may illuminate some of the causative factors in the
pathophysiologic and clinical events of the sepsis syn-
drome. Furthermore, the marker itself may prove to be a
therapeutic target.
Serum levels of ProCT as well as its component peptides
are massively elevated in burns [11], heat stroke [21], systemic
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Figure 3
Relationship between inoculum of Escherichia coli and total
immunoreactive calcitonin (iCT). Low dose = 1.0´108cfu/pellet,
medium dose = 5.0´108cfu/pellet, high dose = 1.0´109cfu/pellet,
and highest dose = 2.0´109cfu/pellet. *Statistically distinct, except
between low and medium doses, per one-way ANOVA, P=0.001.
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Figure 4
Comparison of chromatographs from septic human serum (a) and
pooled septic hamster serum (b). The dominant peak in each graph
has an estimated elution position of 0.2 KaV, which corresponds to the
elution position of human procalcitonin (ProCT) [17]. CT, calcitonin;
CT:CCP-1, conjoined calcitonin:calcitonin carboxypeptide-I.
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1.0infections [13], and other inflammatory states [12,22]. Using
an antiserum to CT which recognizes the free mature CT,
the immature CT within the ProCT molecule, and the con-
joined CT:CCP-1 peptide, we have demonstrated that
levels of serum total iCT are also elevated in the septic
hamster. Then, utilizing gel filtration techniques, we
showed that much of this iCT was in the form of ProCT;
this is similar to the human subject with sepsis [17,23]. Our
findings indicate a positive correlation between ProCT
component peptides and the degree of sepsis. In this
model, the series of metabolic experiments furthermore
reveal that ProCT is temporally associated with and
inversely correlated with serum total calcium levels.
CT is a single chain, 32-amino acid peptide that originates
from the CALC-I gene on chromosome 11 [16]. In
humans the highest concentration of tissue iCT is in the
parafollicular cells of the thyroid gland. However, iCT can
be detected throughout the body in NE cells of various
tissues. Indeed, in humans the lungs contain more total
iCT than does the thyroid gland [24]. 
While mature CT has diverse effects on various target
tissues, its overall physiologic significance in normal indi-
viduals is not well understood. In health, its principal role
is to protect against excessive bone turnover during times
of increased need by attenuating the activity of osteoclasts
[25]. CT and its precursors, however, may exert other
effects in health or in disease [16].
The polypeptide precursor of CT, pre-procalcitonin,
undergoes cleavage of its leader sequence early in post-
translational processing to yield ProCT, and several con-
stituent peptides (Fig 1). In normal, regulated secretion,
ProCT is trafficked through the Golgi apparatus and then
packaged into dense-core secretory vesicles [26,27]. Proteo-
lytic processing within the trans-Golgi and the secretory
vesicles culminates in the formation of the active, mature
secretory product, CT, which is released by exocytosis at
the apical surface of the NE cell. In the absence of an
appropriate signal at the plasma membrane, these vesicles
serve as storage repositories for mature CT.
In severe systemic inflammation in humans, however,
enormous levels of ProCT and other component peptides
appear in the serum, while mature serum CT remains
normal or only minimally elevated [17]. The cellular
source of this increase in serum levels, and the reasons
that ProCT and its component peptides are not processed
to the mature hormone, are unknown. In inflammatory
states, ProCT and its related peptides appear to be
secreted by a continuous bulk-flow constitutive pathway,
in which only limited conversion to mature CT occurs
[28]. One might postulate that severe inflammation causes
such a profound hypersynthesis of the prohormone that
the NE endoproteolytic machinery is overwhelmed. This
may result in a marked shift to the constitutive pathway of
secretion, resulting in an incomplete processing of precur-
sors. In this respect, a shift to constitutive secretion has
been reported to occur by the experimental induction of
dysfunctional prohormone convertase enzymes or by
injury to the plasma membrane [29]. Perhaps some
cytokines may induce constitutive secretion by such a
process [30,31]. It is also possible that ProCT and its com-
ponent peptides are released by non-NE cells, which nor-
mally possess regulatory mechanisms limiting the
expression of ProCT mRNA; these inhibitory mechanisms
may be deregulated by unusually high levels of inflamma-
tory mediators. Stimulation of synthesis in such non-NE
cells would result in a preferential production of ProCT
because these cells lack the enzymes for complete prohor-
monal processing.
It is unknown what impact, if any, this increase of ProCT
and related peptides has on patients. Hypocalcemia is a
common finding in critically ill and especially septic
patients. Indeed, the development of hypocalcemia in the
critically ill has been shown to be associated with a poor
prognosis [32,33]. ProCT contains within its structure the
immature CT molecule; therefore, very high and sus-
tained levels of ProCT might mimic one of the phar-
maco/physiologic activities of CT, which is the lowering of
serum calcium levels. In our experiments we noted that
total iCT levels peaked at 12h following the septic insult.
This was concurrent with a significant decrease in serum
total calcium. Nevertheless, this association does not
prove a causal relationship between elevated ProCT
levels and hypocalcemia. Also, the relationship with
ionized calcium was not determined in this study. 
The early and marked hypersecretion of ProCT and its com-
ponent peptides in inflammatory states makes them promis-
ing serum markers for the sepsis syndrome. These peptides
are released into the central circulation and may act systemi-
cally, as opposed to many of the known mediators of sepsis,
which are released locally and often act in an autocrine or
paracrine fashion. An important feature of ProCT and some
of its component peptides are their long half-lives, which
contribute to their potential usefulness as serum markers.
Indeed, elevated levels of ProCT peptides have been found
to persist at least 24h following an appropriate stimulus, in
contradistinction to other markers, such as tumor necrosis
fctor-a, whose levels may be only transiently elevated after
an inflammatory challenge [34,35]. Thus, they provide a
long-lasting target to evaluate the effects of immunoneutral-
ization. Accordingly, we recently reported that ProCT
markedly contributes to mortality in experimental sepsis,
and that immunoneutralization of this molecule diminishes
mortality in our model of hamster sepsis [36].
In summary, our animal experiments demonstrate an asso-
ciation between levels of serum ProCT and its component
Research paper  Calcitonin precursors in sepsis Steinwald et al 15peptides with the degree of sepsis, reinforcing clinical
findings that these peptides are useful markers for this
condition, and may predict mortality. Further experiments
to examine the cellular source, pathophysiology and meta-
bolic activity of ProCT and its component peptides are
warranted. Such studies may determine the role of these
hormonal peptides in inflammation and sepsis.
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